All In Biotech

Drug Trial Radar · NCT07110766

Phase Ib Clinical Study on the Efficacy and Safety of MDR-001 in Patients Who Are Obesity or Overweight

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ib Clinical Study to Evaluate the Efficacy and Safety of Small Molecule MDR-001 Tablets Administered Orally for 12 Weeks Treatment in Overweight or Obesity Participants

Last checked: Nov 19, 2026Latest source record: Aug 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Aug 9, 2025

Primary completion

Sep 15, 2025

Study completion Oct 30, 2025

Sponsor

Lead sponsor
MindRank AI LtdIndustry
Sponsor type
Industry
First posted
Aug 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 12 weeks, multicenter, randomized, double-blind, placebo, parallel-controlled Phase Ib trail comparing the efficacy and safety of MDR-001 tablet versus placebo as an adjunct to a reduced calorie diet and increased physical activity in subjects with overweight or obesity, and to explore the optimal dose selection to support the subsequent Pivotal trial.

Conditions

  • Obesity &Amp; Overweight

Interventions

  • MDR-001Drug

    Oral administration of small molecule MDR-001 tablets

  • PlaceboDrug

    Administered orally placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Body Weight From Baseline at Week 12Time frame: Baseline, Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The first hospital of Jilin University

    Ch’ang-ch’un, Jilin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.